DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
6532
4-ISOTHIOUREIDOBUTYRONITRILE
2
Small molecule
Investigational
Unknown
Unknown
Neoplasms; Ovarian Neoplasms
Unknown
4-ISOTHIOUREIDOBUTYRONITRILE
×
Maximum Phase:
2
First Approval:
None
UNII:
C3059TG1KN
Molecule Type:
Small molecule
Molecular Formula:
C5H9N3S
Molecular Weight:
143.22
AlogP:
0.92
PSA:
73.66
HBD:
2.0
HBA:
#RotB:
3.0
Source:
EC-17
2
Small molecule
Investigational
Unknown
Unknown
Neoplasms; Carcinoma, Renal Cell
Unknown
EC-17
×
Maximum Phase:
2
First Approval:
None
UNII:
V7YQ6134AE
Molecule Type:
Small molecule
Molecular Formula:
C42H36N10O10S
Molecular Weight:
872.88
AlogP:
3.03
PSA:
310.33
HBD:
9.0
HBA:
#RotB:
13.0
Source:
SERLOPITANT
2
Small molecule
Investigational
Unknown
Unknown
Epidermolysis Bullosa; Pruritus
Neurokinin 1 receptor antagonist
SERLOPITANT
×
Maximum Phase:
2
First Approval:
None
UNII:
277V92K32B
Molecule Type:
Small molecule
Molecular Formula:
C29H28F7NO2
Molecular Weight:
555.53
AlogP:
7.68
PSA:
29.54
HBD:
0.0
HBA:
#RotB:
5.0
Source:
MIRIDESAP
2
Small molecule
Investigational
Unknown
Unknown
HIV Infections; Immunoglobulin Light-chain Amyloidosis; Amyloidosis
Serum amyloid P-component cross-linking agent
MIRIDESAP
×
Maximum Phase:
2
First Approval:
None
UNII:
WO97N24A47
Molecule Type:
Small molecule
Molecular Formula:
C16H24N2O6
Molecular Weight:
340.38
AlogP:
0.7
PSA:
115.22
HBD:
2.0
HBA:
#RotB:
7.0
Source:
TABIMORELIN
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Cytochrome P450 3A4 inhibitor
TABIMORELIN
×
Maximum Phase:
2
First Approval:
None
UNII:
L51CBE03KF
Molecule Type:
Small molecule
Molecular Formula:
C32H40N4O3
Molecular Weight:
528.7
AlogP:
3.71
PSA:
95.74
HBD:
2.0
HBA:
#RotB:
11.0
Source:
RILEMATOVIR
2
Small molecule
Investigational
Unknown
Unknown
Liver Diseases; Respiratory Syncytial Virus Infections; Infections
Fusion glycoprotein F0 inhibitor
RILEMATOVIR
×
Maximum Phase:
2
First Approval:
None
UNII:
NQ99E8OH3P
Molecule Type:
Small molecule
Molecular Formula:
C21H20ClF3N4O3S
Molecular Weight:
500.93
AlogP:
3.85
PSA:
78.89
HBD:
0.0
HBA:
#RotB:
7.0
Source:
TOP-1288
2
Small molecule
Investigational
Unknown
Unknown
Colitis, Ulcerative
Unknown
TOP-1288
×
Maximum Phase:
2
First Approval:
None
UNII:
19ZTZ9YC4O
Molecule Type:
Small molecule
Molecular Formula:
C43H49N7O9S
Molecular Weight:
839.97
AlogP:
6.88
PSA:
200.36
HBD:
5.0
HBA:
#RotB:
19.0
Source:
DS-1001A
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
DS-1001A
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
C25H18Cl3FN2O4
Molecular Weight:
535.79
AlogP:
7.56
PSA:
85.33
HBD:
1.0
HBA:
#RotB:
5.0
Source:
TETRASUL
2
Small molecule
Investigational
Unknown
Unknown
Rosacea
Unknown
TETRASUL
×
Maximum Phase:
2
First Approval:
None
UNII:
BEO7JP5U0R
Molecule Type:
Small molecule
Molecular Formula:
C12H6Cl4S
Molecular Weight:
324.06
AlogP:
6.45
PSA:
0.0
HBD:
0.0
HBA:
#RotB:
2.0
Source:
EMERAMIDE
2
Small molecule
Investigational
Unknown
Unknown
beta-Thalassemia; Mercury Poisoning; Pulmonary Disease, Chronic Obstructive
Antioxidant and metal chelator
EMERAMIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
4U7K5X4ANS
Molecule Type:
Small molecule
Molecular Formula:
C12H16N2O2S2
Molecular Weight:
284.41
AlogP:
1.01
PSA:
58.2
HBD:
4.0
HBA:
#RotB:
6.0
Source:
POLYCARBOPHIL
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Bulk forming laxative
POLYCARBOPHIL
×
Maximum Phase:
2
First Approval:
None
UNII:
W25LM17A4W
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
NIRAPARIB TOSYLATE MONOHYDRATE
2
Small molecule
Investigational
Unknown
Unknown
Breast Neoplasms; Neoplasms; Fallopian Tube Neoplasms; Ovarian Neoplasms; Peritoneal Neoplasms
Poly [ADP-ribose] polymerase-1 inhibitor
NIRAPARIB TOSYLATE MONOHYDRATE
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
C26H30N4O5S
Molecular Weight:
510.62
AlogP:
2.59
PSA:
72.94
HBD:
2.0
HBA:
#RotB:
3.0
Source:
ASLAN-003
2
Small molecule
Investigational
Unknown
Unknown
Alopecia Areata; Leukemia, Myeloid, Acute
Dihydroorotate dehydrogenase inhibitor
ASLAN-003
×
Maximum Phase:
2
First Approval:
None
UNII:
I58WE41H6X
Molecule Type:
Small molecule
Molecular Formula:
C19H14F2N2O3
Molecular Weight:
356.33
AlogP:
4.48
PSA:
71.45
HBD:
2.0
HBA:
#RotB:
5.0
Source:
CENTHAQUINE
2
Small molecule
Investigational
Unknown
Unknown
Cardiovascular Diseases; Shock
Unknown
CENTHAQUINE
×
Maximum Phase:
2
First Approval:
None
UNII:
QD4VI0J9T5
Molecule Type:
Small molecule
Molecular Formula:
C22H25N3
Molecular Weight:
331.46
AlogP:
3.91
PSA:
19.37
HBD:
0.0
HBA:
#RotB:
4.0
Source:
R-343
2
Small molecule
Investigational
Unknown
Unknown
Asthma
Tyrosine-protein kinase SYK inhibitor
R-343
×
Maximum Phase:
2
First Approval:
None
UNII:
Y4069R7J86
Molecule Type:
Small molecule
Molecular Formula:
C21H17F3N6O4
Molecular Weight:
474.4
AlogP:
3.15
PSA:
126.5
HBD:
4.0
HBA:
#RotB:
7.0
Source:
MANNOSE-6-PHOSPHATE
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
MANNOSE-6-PHOSPHATE
×
Maximum Phase:
2
First Approval:
None
UNII:
C77UQ006XD
Molecule Type:
Small molecule
Molecular Formula:
C6H13O9P
Molecular Weight:
260.13
AlogP:
-3.1
PSA:
156.91
HBD:
6.0
HBA:
#RotB:
3.0
Source:
SEPETAPROST
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Prostanoid EP3 receptor agonist
SEPETAPROST
×
Maximum Phase:
2
First Approval:
None
UNII:
79O7855J4G
Molecule Type:
Small molecule
Molecular Formula:
C26H36F2O6
Molecular Weight:
482.56
AlogP:
4.17
PSA:
85.22
HBD:
2.0
HBA:
#RotB:
10.0
Source:
IFIDANCITINIB
2
Small molecule
Investigational
Unknown
Unknown
Alopecia; Dermatitis, Atopic
Unknown
IFIDANCITINIB
×
Maximum Phase:
2
First Approval:
None
UNII:
R105E71J13
Molecule Type:
Small molecule
Molecular Formula:
C20H18FN5O3
Molecular Weight:
395.39
AlogP:
4.16
PSA:
105.07
HBD:
3.0
HBA:
#RotB:
5.0
Source:
SISUNATOVIR
2
Small molecule
Investigational
Unknown
Unknown
Liver Diseases; Respiratory Syncytial Virus Infections
Fusion glycoprotein F0 inhibitor
SISUNATOVIR
×
Maximum Phase:
2
First Approval:
None
UNII:
KE63TTO7WK
Molecule Type:
Small molecule
Molecular Formula:
C23H22F4N4O
Molecular Weight:
446.45
AlogP:
4.56
PSA:
64.15
HBD:
1.0
HBA:
#RotB:
6.0
Source:
AZD-7624
2
Small molecule
Investigational
Unknown
Unknown
Inflammation; Asthma; Pulmonary Disease, Chronic Obstructive
MAP kinase p38 alpha inhibitor
AZD-7624
×
Maximum Phase:
2
First Approval:
None
UNII:
3P4CR02JTD
Molecule Type:
Small molecule
Molecular Formula:
C25H22N2O
Molecular Weight:
366.46
AlogP:
5.78
PSA:
41.99
HBD:
1.0
HBA:
#RotB:
5.0
Source:
APX-3330
2
Small molecule
Investigational
Unknown
Unknown
Neoplasms
DNA-(apurinic or apyrimidinic site) lyase inhibitor
APX-3330
×
Maximum Phase:
2
First Approval:
None
UNII:
11267UI968
Molecule Type:
Small molecule
Molecular Formula:
C21H30O6
Molecular Weight:
378.47
AlogP:
4.11
PSA:
89.9
HBD:
1.0
HBA:
#RotB:
12.0
Source:
PTEROSTILBENE
2
Small molecule
Investigational
Unknown
Unknown
Acute Kidney Injury; Endometrial Neoplasms
Unknown
PTEROSTILBENE
×
Maximum Phase:
2
First Approval:
None
UNII:
26R60S6A5I
Molecule Type:
Small molecule
Molecular Formula:
C16H16O3
Molecular Weight:
256.3
AlogP:
3.58
PSA:
38.69
HBD:
1.0
HBA:
#RotB:
4.0
Source:
JNJ-17166864
2
Small molecule
Investigational
Unknown
Unknown
Rhinitis, Allergic, Seasonal
Unknown
JNJ-17166864
×
Maximum Phase:
2
First Approval:
None
UNII:
VF9KM790TY
Molecule Type:
Small molecule
Molecular Formula:
C21H25Cl2N2O2+
Molecular Weight:
408.35
AlogP:
5.0
PSA:
38.33
HBD:
1.0
HBA:
#RotB:
5.0
Source:
PICEID
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
PICEID
×
Maximum Phase:
2
First Approval:
None
UNII:
XM261C37CQ
Molecule Type:
Small molecule
Molecular Formula:
C20H22O8
Molecular Weight:
390.39
AlogP:
0.45
PSA:
139.84
HBD:
6.0
HBA:
#RotB:
5.0
Source:
VERINURAD
2
Small molecule
Investigational
Unknown
Unknown
Gout; Heart Failure; Hyperuricemia; Renal Insufficiency, Chronic
Solute carrier family 22 member 12 inhibitor
VERINURAD
×
Maximum Phase:
2
First Approval:
None
UNII:
12WJ62D047
Molecule Type:
Small molecule
Molecular Formula:
C20H16N2O2S
Molecular Weight:
348.43
AlogP:
4.73
PSA:
73.98
HBD:
1.0
HBA:
#RotB:
4.0
Source:
NM404
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
NM404
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
PF-00489791
2
Small molecule
Investigational
Unknown
Unknown
Diabetic Nephropathies; Hypertension; Hypertension, Pulmonary; Peripheral Vascular Diseases; Raynaud Disease
Phosphodiesterase 5A inhibitor
PF-00489791
×
Maximum Phase:
2
First Approval:
None
UNII:
2S27T3DSZ3
Molecule Type:
Small molecule
Molecular Formula:
C20H28N8O4S
Molecular Weight:
476.56
AlogP:
1.46
PSA:
144.23
HBD:
2.0
HBA:
#RotB:
10.0
Source:
UC1010
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
UC1010
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
PF-4191834
2
Small molecule
Investigational
Unknown
Unknown
Asthma; Osteoarthritis, Knee
Arachidonate 5-lipoxygenase inhibitor
PF-4191834
×
Maximum Phase:
2
First Approval:
None
UNII:
YX55DXP4T1
Molecule Type:
Small molecule
Molecular Formula:
C22H23N3O2S
Molecular Weight:
393.51
AlogP:
3.77
PSA:
70.14
HBD:
1.0
HBA:
#RotB:
5.0
Source:
SQ109
2
Small molecule
Investigational
Unknown
Unknown
Helicobacter Infections; Tuberculosis
Unknown
SQ109
×
Maximum Phase:
2
First Approval:
None
UNII:
9AU7XUV31A
Molecule Type:
Small molecule
Molecular Formula:
C22H38N2
Molecular Weight:
330.56
AlogP:
4.68
PSA:
24.06
HBD:
2.0
HBA:
#RotB:
9.0
Source:
FLUOROFURANYLNORPROGESTERONE
2
Small molecule
Investigational
Unknown
Unknown
Breast Neoplasms
Unknown
FLUOROFURANYLNORPROGESTERONE
×
Maximum Phase:
2
First Approval:
None
UNII:
K56K9G4PPM
Molecule Type:
Small molecule
Molecular Formula:
C25H29FO5
Molecular Weight:
428.5
AlogP:
4.72
PSA:
65.74
HBD:
0.0
HBA:
#RotB:
3.0
Source:
TONABERSAT
2
Small molecule
Investigational
Unknown
Unknown
Migraine with Aura; Migraine without Aura; Post-Acute COVID-19 Syndrome
Unknown
TONABERSAT
×
Maximum Phase:
2
First Approval:
None
UNII:
2XD9773ZMN
Molecule Type:
Small molecule
Molecular Formula:
C20H19ClFNO4
Molecular Weight:
391.83
AlogP:
3.68
PSA:
75.63
HBD:
2.0
HBA:
#RotB:
3.0
Source:
PROPIONIC ACID
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
PROPIONIC ACID
×
Maximum Phase:
2
First Approval:
None
UNII:
JHU490RVYR
Molecule Type:
Small molecule
Molecular Formula:
C3H6O2
Molecular Weight:
74.08
AlogP:
0.48
PSA:
37.3
HBD:
1.0
HBA:
#RotB:
1.0
Source:
SONEDENOSON
2
Small molecule
Investigational
Unknown
Unknown
Diabetic Foot
Adenosine A2a receptor agonist
SONEDENOSON
×
Maximum Phase:
2
First Approval:
None
UNII:
2OT4KAG5JL
Molecule Type:
Small molecule
Molecular Formula:
C18H20ClN5O5
Molecular Weight:
421.84
AlogP:
0.29
PSA:
148.77
HBD:
4.0
HBA:
#RotB:
6.0
Source:
EMRICASAN
2
Small molecule
Investigational
Unknown
Unknown
Diabetes Mellitus; Digestive System Diseases; Liver Diseases; Severe Acute Respiratory Syndrome; Hepatitis, Alcoholic; Hepatitis C, Chronic; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease
Caspase inhibitor
EMRICASAN
×
Maximum Phase:
2
First Approval:
None
UNII:
P0GMS9N47Q
Molecule Type:
Small molecule
Molecular Formula:
C26H27F4N3O7
Molecular Weight:
569.51
AlogP:
2.59
PSA:
150.9
HBD:
4.0
HBA:
#RotB:
10.0
Source:
1
2
…
92
93
94
95
96
97
98
…
186
187
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA